EFFECTS OF LOVASTATIN AND GEMFIBROZIL ON HIGH-DENSITY-LIPOPROTEIN SUBFRACTION DENSITY AND COMPOSITION IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引:0
|
作者
TILLYKIESI, M [1 ]
TIKKANEN, MJ [1 ]
机构
[1] UNIV HELSINKI,DEPT MED 1,SF-00290 HELSINKI 29,FINLAND
来源
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The effects of gemfibrozil and lovastatin treatment on composition and hydrated density distribution of high-density lipoprotein (HDL) were studied in 21 patients with heterozygous familial hypercholesterolemia with the use of HDL density gradient ultracentrifugation. At baseline the patients with familial hypercholesterolemia had a markedly reduced or missing HDL2 subfraction and their HDL3 was more dense with reduced content of cholesteryl ester and increased content of triglyceride compared with HDL of, control subjects with normal lipid values. Gemfibrozil and lovastatin caused primarily similar alterations in HDL components in HDL2 and HDL3 subtractions. Both agents increased apolipoprotein AI and apolipoprotein All concentrations significantly in HDL2, whereas the apolipoprotein changes in HDL, were relatively smaller. The difference between the effects of these two agents was related to the HDL lipid composition. Gemfibrozil increased the cholesterol concentrations of HDL2 and HDL3 (p < 0.05 for both), and lovastatin caused significant increases in HDL2 (p < 0.05) and HDL3 phospholipids (p < 0.01). The observed similarity of qualitative alterations in HDL subfractions produced by these two agents in patients with familial hypercholesterolemia differs from those reported in other types of hyperlipidemia and is probably a consequence of the basic abnormalities in HDL that are characteristic of familial hy percholesterolemia.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 50 条
  • [1] COMPARISON OF GEMFIBROZIL AND LOVASTATIN IN PATIENTS WITH HIGH LOW-DENSITY-LIPOPROTEIN AND LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS
    MCKENNEY, JM
    BARNETT, MD
    WRIGHT, JT
    PROCTOR, JP
    ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (09) : 1781 - 1787
  • [2] MARKED INTERINDIVIDUAL VARIABILITY IN HIGH-DENSITY-LIPOPROTEIN SUBFRACTION COMPOSITION
    SADY, SP
    HERBERT, PN
    HENDERSON, LO
    MCKINLAY, SM
    CARLETON, RJ
    ARTERIOSCLEROSIS, 1987, 7 (05): : A507 - A507
  • [3] CHANGE IN COMPOSITION OF HIGH-DENSITY-LIPOPROTEIN DURING GEMFIBROZIL THERAPY
    SORISKY, A
    OOI, TC
    SIMO, IE
    MEUFFELS, M
    HINDMARSH, JT
    NAIR, R
    ATHEROSCLEROSIS, 1987, 67 (2-3) : 181 - 189
  • [4] ETHANOL INDUCED ALTERATIONS IN HIGH-DENSITY-LIPOPROTEIN SUBFRACTION COMPOSITION AND METABOLISM
    HOJNACKI, J
    CLUETTEBROWN, J
    MULLIGAN, J
    HAGAN, S
    OSMOLSKI, T
    CLINICAL RESEARCH, 1986, 34 (03): : A857 - A857
  • [5] THE EFFECT OF SIMVASTATIN TREATMENT ON THE LOW-DENSITY-LIPOPROTEIN SUBFRACTION PROFILE AND COMPOSITION IN FAMILIAL HYPERCHOLESTEROLEMIA
    DEGRAAF, J
    DEMACKER, PNM
    STALENHOEF, AFH
    NETHERLANDS JOURNAL OF MEDICINE, 1993, 43 (5-6): : 254 - 261
  • [6] THE EFFICACY OF GEMFIBROZIL THERAPY FOR RAISING HIGH-DENSITY-LIPOPROTEIN LEVELS
    WEIS, S
    KUDCHODKAR, BJ
    CLEARFIELD, MB
    LACKO, AG
    ARTERY, 1992, 19 (06) : 353 - 367
  • [7] EFFECTS OF LOVASTATIN ON HIGH-DENSITY-LIPOPROTEIN SUBFRACTIONS IN HYPERCHOLESTEROLEMIC PATIENTS WITH PERIPHERAL VASCULAR-DISEASE
    TILLYKIESI, M
    MATTILA, SP
    TIKKANEN, MJ
    ANGIOLOGY, 1993, 44 (02) : 129 - 137
  • [8] COMPARATIVE EFFECTS OF GEMFIBROZIL, PHENYTOIN, AND NICOTINIC-ACID ON SERUM HIGH-DENSITY-LIPOPROTEIN
    BELL, HH
    DITTMEIER, GE
    CHEST, 1986, 89 (06) : S474 - S474
  • [9] APOLIPOPROTEIN M AND HIGH-DENSITY LIPOPROTEIN SUBFRACTION LEVELS IN NEWLY DIAGNOSED, UNTREATED FAMILIAL HYPERCHOLESTEROLEMIA
    Nadro, B.
    Szentpeteri, A.
    Juhasz, L.
    Seres, I.
    Pall, D.
    Paragh, G.
    Harangi, M.
    ATHEROSCLEROSIS, 2019, 287 : E214 - E214
  • [10] EFFECT OF A HIGH-DOSE OF GEMFIBROZIL IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND DECREASED HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL
    KAFONEK, SD
    CLOEY, TA
    BACHORIK, PS
    KWITEROVICH, PO
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (10): : 1271 - 1281